In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews (10/2010)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Eyeing New Drugs For Glaucoma," features profiles of Altheos, Amakem and Mimetogen Pharmaceuticals. Plus these Start-Ups Across Health Care: Aragon Surgical, Arcarios, Carolina BioPharm, Miromatrix Medical and Pathogenica.

You may also be interested in...



Aragon Surgical Inc.

Unlike the unwieldy "Jaws" of the blockbuster movie, the clamping jaws located at the tip of a new electrosurgical instrument from Aragon Surgical. are designed to help surgeons precisely seal and cut both tissues and vessels easier, faster, and more durably. The Caiman system is powered by proprietary Lektrafuse technology, consisting of a radiofrequency energy generator that delivers bipolar energy via a sophisticated algorithm.

Miromatrix Medical Inc.

Regenerative medicine start-up Miromatrix Medical is working to commercialize a technology known as perfusion decellularization. Its proprietary, patent-protected technology involves the decellularization of any vascularized tissue, up to and including whole organs, leaving behind a completely preserved native scaffold (matrix) that retains the original architecture, mechanical properties and vascular network of the tissue or organ. This scaffold can then be repopulated with vascular- and organ-specific regenerative cells and, under controlled conditions in a bioreactor, a biocompatible, functioning organ or tissue is created.

Pathogenica Inc.

Pathogenica, co-founded by Harvard's George Church, PhD, views itself as an "apps" company for a variety of human genome sequencing platforms. Its BioDetection system has the potential to screen thousands of samples, each tested for hundreds of unique pathogen strains at a predicted cost of less than one dollar per pathogen. The start-up aims to enable effective and affordable pathogen sequencing in a wide range of markets - physician, veterinary, and farming - not just scientific.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel